# Diabetes Research Hub — Monitor Report
**Run date:** 2026-08-09 (automated review run)
**Reviewer:** Hub monitor (read-only; no source files modified)

---

## TL;DR — What's Actionable

**The collection pipeline is still down — day 23 of a confirmed outage.** Every "latest" data file is frozen at **2026-07-17**. This is now the *third consecutive* daily report to flag the same freeze (`monitor_report_2026-08-07.md`, `..._08-08.md`, and this one). No collector script has re-run in the 24 hours since yesterday's report. This is not staleness — it's a stopped job that needs manual attention. [Certain — no `clinical_trials_snapshot_*` or `pubmed_recent_snapshot_*` file exists after 2026-07-17.]

**Nothing in the underlying data changed since yesterday.** No new snapshots, so nothing new to diff. The only external item still worth carrying forward: **retatrutide's TRIUMPH Phase 3 type 2 diabetes readout (~2026-07-23)** landed *inside the outage window* and is absent from your trial and PubMed data.

**Do this first:** re-run the three baseline scripts. If they fail on *execution* (not just "no new data"), the scheduler/cron for the collectors is the real fault, not the scripts.

```
python baseline_clinical_trials.py
python baseline_pubmed_alerts.py
python project1_literature_gap_analysis.py
python hub_monitor.py
```

---

## File System Status

| File | Last modified | Age | Status |
|------|--------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 23 d | ⚠️ STALE (>14 d) |
| `pubmed_recent_latest.json` | 2026-07-17 | 23 d | ⚠️ STALE (>14 d) |
| `hub_monitor_report.md` | 2026-07-17 | 23 d | ⚠️ STALE (>14 d) |
| `literature_gap_data.json` | 2026-07-18 | 22 d | ⚠️ STALE (>14 d) |
| `literature_gap_report.md` | 2026-08-08 | 1 d | Fresh file — but re-analyzes frozen 2026-07-17 PubMed data |
| `agent_state.json` | 2026-08-08 | 1 d | Current (backup rotation still running) |

**Evidence — how I know the freeze is real, not a filesystem artifact:**
- Dated snapshots run continuously **2026-03-15 → 2026-07-17, then stop.** A directory scan for any snapshot after 2026-07-17 returns nothing. [Certain]
- Internal metadata timestamps confirm it: `clinical_trials_latest.json` `generated: 2026-07-17T02:05:53` (total_trials: 858); `pubmed_recent_latest.json` `generated: 2026-07-17T02:06:39` (158 unique papers). [Certain]
- `literature_gap_report.md` carries a fresh 2026-08-08 timestamp, but its own header still reads *"Date range: 2020/01/01 to 2026/07/17."* It re-ran on cached data and produced identical rankings. Its freshness is cosmetic. [Certain]

**Root cause [Likely]:** `baseline_clinical_trials.py`, `baseline_pubmed_alerts.py`, and `hub_monitor.py` have not executed since 2026-07-17. Only the gap script and the `agent_state.json` backup rotation still fire. A 23-day gap against a previously *daily* cadence points to a failed or disabled scheduler rather than a quiet news period.

---

## Clinical Trial Changes

**No new snapshot since 2026-07-17, so there is nothing new to diff.** Figures below are the frozen state, carried for reference only. Source: `clinical_trials_latest.json` (858 trials).

**Category counts (frozen 2026-07-17):**

| Category | Trials |
|----------|--------|
| Diabetes Technology (Devices) | 236 |
| Recently Completed with Results | 321 |
| T1D Cure & Cell Therapy | 152 |
| T2D Novel Therapies (Ph 2–3) | 147 |
| T1D Immunotherapy & Prevention | 76 |

**Key Phase 3 trials still flagged RECRUITING** (52 total Phase 3 recruiting; highest-priority sponsors):

- **NCT06832410 / NCT04786262** — Vertex, VX-880 (zimislecel), Phase 3 — islet cell therapy for T1D
- **NCT07222332 / NCT07222137** — Eli Lilly, baricitinib (LY3009104), Phase 3 — beta-cell preservation / Stage 3 T1D delay
- **NCT07076199** — Novo Nordisk, insulin icodec (weekly), Phase 3
- **NCT07564414** — Novo Nordisk, CagriSema, Phase 3
- **NCT07088068** — Sanofi, teplizumab comparison, Phase 3

**Last observed status changes (Jul 13 → Jul 17, before the freeze):** 5 trials moved NOT_YET_RECRUITING → RECRUITING (incl. AstraZeneca ecoglipron NCT07662044/135/213, Novo NCT07668388); 1 moved RECRUITING → ACTIVE_NOT_RECRUITING (Lilly NCT07215312). **No new results were posted in that window.** Everything after 2026-07-17 is unobserved.

**Last new trials captured (Jul 13 → Jul 17):** NCT07699380 (U. Washington, Ph 2), NCT07702890 (Gubra A/S, Ph 1–2 first-in-human). Over the full tracked arc, the corpus grew from 746 trials (Mar 15) to 858 (Jul 17), +174 net.

---

## PubMed Highlights

**Frozen at 2026-07-17** — 158 unique papers, 16 domains, 30-day lookback. Nothing new since. Carried for reference:

**Cross-domain papers (highest priority — appear in ≥2 alert domains):**
- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — Diabetes AI/ML + Closed Loop AP + Health Equity (3 domains). Directly relevant to Tier 1 Area 6 (Epidemiological / equity) and Area 5 (AI/ML).
- **[42419792]** *Comparative effects of drugs for adults with overweight or obesity (systematic review)* — orforglipron + retatrutide + CagriSema (3 key therapies).
- **[42411999]** *Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Transplant* — T1D Stem Cell Cure + Immunotherapy.
- **[42453334]** *Harnessing Noncoding RNAs for Diabetes Research* — Biomarker + LADA.
- **[42458730] / [42459212]** two multi-omics precision-nutrition papers — Microbiome + Multi-Omics (Tier 1 Area 1).

**Key-therapy mention counts (frozen):** dapagliflozin 52 hits / orforglipron 10 / CagriSema 6 / retatrutide 4 / teplizumab 4 / icodec 3 / baricitinib 2 / **zimislecel 0**. Zimislecel's zero count is notable given Vertex's active Phase 3 program — a terminology-coverage gap (papers likely indexed under "VX-880"), worth checking the query string when the pipeline is restored. [Likely]

---

## Gap Analysis Summary

From `literature_gap_report.md` (re-run 2026-08-08 but on frozen 2026-07-17 PubMed data; rankings unchanged). **Validation level: BRONZE** — single analytical source, requires expert confirmation per Research Doctrine.

**Top 5 under-researched intersections (Gap Score 100, zero joint pubs):**

| # | Intersection | Tier 1 alignment |
|---|--------------|------------------|
| 1 | Treg / CAR-T × Neuropathy | — |
| 2 | Beta Cell Regen × Health Equity | ✅ Area 6 (equity) |
| 3 | Treg / CAR-T × Health Equity | ✅ Area 6 |
| 4 | Glucokinase × Health Equity | ✅ Area 6 |
| 5 | Gene Therapy × LADA | partial (Area 2 synthesis) |
| (6) | Drug Repurposing × Health Equity | ✅ Areas 4 + 6 |

**Doctrine note:** four of the top six gaps involve **Health Equity**, which maps to Tier 1 Area 6 (Epidemiological Data Analysis) and is a public-data, computationally tractable target. These are the strongest candidates for a literature-synthesis contribution — but each is BRONZE and must be verified against Cochrane/PROSPERO for existing reviews before any claim is made.

---

## Breaking News (web check, last 7 days)

**No confirmed major FDA action or Phase 3 readout in the 2026-08-02 → 08-09 window.** [Likely — based on web search; absence of news is harder to prove than presence.]

Carry-forward items that fell **inside the outage window** and are therefore missing from your snapshots:
- **Retatrutide TRIUMPH Phase 3 (T2D), ~2026-07-23** — first Phase 3 T2D + obesity readout for Lilly's triple GIP/GLP-1/glucagon agonist: ~1.7–1.9% HbA1c reduction and ~11.5–15.3% weight loss at 40 weeks vs placebo. Significant; not in `clinical_trials_latest.json` or PubMed data. [Likely]

Context (pre-outage, likely already captured or predating the corpus, flagged to avoid double-counting):
- **Orforglipron (Foundayo, Lilly)** oral GLP-1 — FDA approval for chronic weight management dated **2026-04-01**, *before* the outage window. Lilly's separate T2D glycemic filing may still be pending; watch for it when the pipeline restarts. [Likely]
- **Teplizumab (Tzield, Sanofi)** pediatric Stage 3 T1D indication — FDA approval **2026-06-12**, also pre-outage. [Certain]

None of these change today's actionable picture; they matter only because the frozen pipeline can't see the two most recent.

---

## Recommended Actions

1. **Restart the collectors — highest priority.** Run `baseline_clinical_trials.py`, `baseline_pubmed_alerts.py`, and `hub_monitor.py`. If they execute cleanly but produce no new snapshot, the fault is the scheduler; if they error, capture the traceback. This is the single blocker to every other finding below. [Certain this is the top action.]
2. **Backfill the outage gap.** Once collectors run, diff the first fresh snapshot against `clinical_trials_snapshot_2026-07-17.json` and `pubmed_recent_snapshot_2026-07-17.json` to recover ~23 days of missed trials, status changes, and papers in one pass.
3. **Manually log the retatrutide TRIUMPH readout** into `Diabetes_Research_Tracker.xlsx` now, tagged as external/unverified, rather than waiting on the pipeline. Evidence level: BRONZE (press/secondary sources) until the primary publication is indexed.
4. **Fix the zimislecel PubMed query** — 0 hits despite an active Vertex Phase 3 program suggests the alert term misses "VX-880." Add the synonym when editing `baseline_pubmed_alerts.py`.
5. **Re-confirm the gap analysis is running on live data**, not cache — `literature_gap_report.md` re-ran 2026-08-08 but against the frozen 2026-07-17 corpus. After the collectors restart, re-run `project1_literature_gap_analysis.py` and verify the header date range advances past 2026-07-17.
6. **Prioritize the Health-Equity gaps** (4 of top 6) for a Tier 1 literature-synthesis contribution — but verify each against Cochrane/PROSPERO first; all are BRONZE.

---

*Generated by Diabetes Research Hub automated monitor — read-only review run. No source files were modified. Confidence tags follow Research Doctrine v1.0: [Certain] = verified from files/primary evidence, [Likely] = strong inference, [Guessing] = gap-fill.*
